# MOG

## Overview
The MOG gene encodes the myelin oligodendrocyte glycoprotein, a type I integral membrane protein that is a minor but significant component of the myelin sheath in the central nervous system (CNS). MOG is a member of the immunoglobulin superfamily and features a single extracellular immunoglobulin variable (IgV) domain, which is crucial for its role in cell-cell adhesion and communication within the CNS (Han2013Myelin‐specific; Peschl2017Myelin). Although it constitutes only a small fraction of the total myelin proteins, MOG is strategically located on the outermost layers of the myelin sheath, making it accessible to the extracellular environment and potentially involved in various signaling pathways (Sechi2022Myelin; Marignier2021Myelinoligodendrocyte). The protein's interactions and structural characteristics suggest it may function as a cell surface receptor or adhesion molecule, contributing to the maintenance and integrity of the myelin sheath (Peschl2017Myelin). MOG has also been implicated in autoimmune demyelinating diseases, where it serves as a target for pathogenic autoantibodies, highlighting its clinical significance in conditions such as MOG antibody-associated disorders (MOGAD) (Oertel2023Delimiting; Tanaka2023Pathogenesis).

## Structure
The myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane protein with a primary structure consisting of a single polypeptide chain of 218 amino acids, including a signal peptide of 27 amino acids (Gardinier1992Myelinoligodendrocyte). MOG is a member of the immunoglobulin superfamily and contains a single extracellular immunoglobulin variable (IgV) domain, which is crucial for its function in cell-cell adhesion (Han2013Myelin‐specific; Peschl2017Myelin). The protein has a molecular weight of approximately 24,962 Da and includes a potential N-glycosylation site at Asn-31, which is important for its stability and solubility (Mathews2020A; Gardinier1992Myelinoligodendrocyte).

The secondary structure of MOG includes beta-sheets and alpha-helices, with specific regions forming beta-sheets and 3_10 helices in the presence of glycan (Mathews2020A). Glycosylation at N31 plays a significant role in maintaining these structures and enhancing the protein's folding pathway (Mathews2020A). MOG can form a dimeric structure, aggregating from a 26-28 kDa form to a 54 kDa form, suggesting a potential quaternary structure (Gardinier1992Myelinoligodendrocyte).

MOG has several splice variant isoforms, which are expressed at different developmental stages and may influence its function and localization (Peschl2017Myelin). These isoforms are found on the cell surface, in the endoplasmic reticulum, and in the endocytic system, with some being secreted (Peschl2017Myelin).

## Function
The myelin oligodendrocyte glycoprotein (MOG) is a minor component of the myelin sheath in the central nervous system (CNS), constituting about 0.05% of total myelin proteins. It is expressed on the outermost layers of the myelin sheath and on the surface of oligodendrocyte cells, making it accessible to the extracellular environment (Sechi2022Myelin; Marignier2021Myelinoligodendrocyte). MOG is involved in the completion and maintenance of the myelin sheath and plays a role in cell-cell communication within the CNS (Marignier2021Myelinoligodendrocyte).

MOG belongs to the immunoglobulin superfamily and features a single extracellular Ig variable domain, a transmembrane domain, and a cytoplasmic tail, which may influence intracellular signaling and localization (Peschl2017Myelin). Although the precise function of MOG is not fully understood, its molecular structure suggests it may act as a cell surface receptor or cell adhesion molecule (Peschl2017Myelin). MOG has been implicated as a receptor for nerve growth factor and a cellular receptor for the Rubella virus, indicating its potential involvement in various signaling pathways (Peschl2017Myelin). Despite its minor presence, MOG's strategic location and unique characteristics make it significant in maintaining myelin integrity and function.

## Clinical Significance
Mutations and alterations in the expression of the MOG gene are associated with several autoimmune demyelinating diseases, collectively known as MOG antibody-associated disorders (MOGAD). These conditions include optic neuritis, acute disseminated encephalomyelitis (ADEM), and transverse myelitis, among others (Oertel2023Delimiting; Tanaka2023Pathogenesis). MOGAD is characterized by the presence of MOG-specific autoantibodies, primarily of the IgG1 subtype, which can activate the complement system and contribute to the disease's pathogenesis (Tanaka2023Pathogenesis).

The expression levels of MOG can influence the distribution and severity of lesions in the central nervous system. For instance, higher MOG expression in the optic nerve compared to the spinal cord may explain the vulnerability of the optic nerve in MOGAD (Corbali2023Pathophysiology). Variations in MOG expression and structure can affect antibody recognition, impacting the clinical presentation and progression of these disorders (Macrini2021Features).

Genetic factors, such as specific HLA subtypes, have been implicated in the susceptibility to MOGAD, with certain alleles like DQB1*05:02 being associated with pediatric-onset cases (Sun2020Myelin). These genetic associations highlight the complex interplay between genetic predisposition and immune response in the development of MOGAD.

## Interactions
Myelin oligodendrocyte glycoprotein (MOG) is involved in various protein-protein interactions that are crucial for its function in the central nervous system. MOG interacts with MEP-1, a zinc-finger protein, and other MOG proteins, such as MOG-1, MOG-4, and MOG-5, in Caenorhabditis elegans. These interactions are essential for the regulation of gene expression via the fem-3 3' untranslated region (UTR) (BELFIORE2002The). MEP-1 and MOG proteins form a nuclear complex that is necessary for the repression of fem-3 mRNA, indicating a role in posttranscriptional regulation (BELFIORE2002The).

In the context of myelin biology, MOG is part of a protein-protein interaction network that includes classical myelin proteins such as myelin basic protein (MBP) and proteolipid protein (PLP). This network is important for myelin biogenesis and maintenance, highlighting MOG's role in cell adhesion, protein trafficking, and signaling pathways (Chasapis2022The). The interactions within this network are critical for understanding the molecular mechanisms underlying myelin-related neurological diseases, such as multiple sclerosis (Chasapis2022The). These interactions suggest that MOG plays a significant role in maintaining the structural integrity and function of myelin sheaths.


## References


[1. (Han2013Myelin‐specific) Huijong Han, Matti Myllykoski, Salla Ruskamo, Chaozhan Wang, and Petri Kursula. Myelin‐specific proteins: a structurally diverse group of membrane‐interacting molecules. BioFactors, 39(3):233–241, January 2013. URL: http://dx.doi.org/10.1002/biof.1076, doi:10.1002/biof.1076. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/biof.1076)

[2. (Oertel2023Delimiting) Frederike Cosima Oertel, Maria Hastermann, and Friedemann Paul. Delimiting mogad as a disease entity using translational imaging. Frontiers in Neurology, December 2023. URL: http://dx.doi.org/10.3389/fneur.2023.1216477, doi:10.3389/fneur.2023.1216477. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2023.1216477)

[3. (Tanaka2023Pathogenesis) Keiko Tanaka, Takeshi Kezuka, Hitoshi Ishikawa, Masami Tanaka, Kenji Sakimura, Manabu Abe, and Meiko Kawamura. Pathogenesis, clinical features, and treatment of patients with myelin oligodendrocyte glycoprotein (mog) autoantibody-associated disorders focusing on optic neuritis with consideration of autoantibody-binding sites: a review. International Journal of Molecular Sciences, 24(17):13368, August 2023. URL: http://dx.doi.org/10.3390/ijms241713368, doi:10.3390/ijms241713368. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms241713368)

[4. (Gardinier1992Myelinoligodendrocyte) M. V. Gardinier, P. Amiguet, C. Linington, and J.‐M. Matthieu. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. Journal of Neuroscience Research, 33(1):177–187, September 1992. URL: http://dx.doi.org/10.1002/jnr.490330123, doi:10.1002/jnr.490330123. This article has 176 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jnr.490330123)

[5. (Mathews2020A) Rita Mathews and L. Ramya. A comparative study for the intermediate states of myelin oligodendrocyte glycoprotein in the absence and presence of glycan – a computational approach. Journal of Molecular Graphics and Modelling, 96:107517, May 2020. URL: http://dx.doi.org/10.1016/j.jmgm.2019.107517, doi:10.1016/j.jmgm.2019.107517. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jmgm.2019.107517)

[6. (Sechi2022Myelin) Elia Sechi, Laura Cacciaguerra, John J. Chen, Sara Mariotto, Giulia Fadda, Alessandro Dinoto, A. Sebastian Lopez-Chiriboga, Sean J. Pittock, and Eoin P. Flanagan. Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad): a review of clinical and mri features, diagnosis, and management. Frontiers in Neurology, June 2022. URL: http://dx.doi.org/10.3389/fneur.2022.885218, doi:10.3389/fneur.2022.885218. This article has 127 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2022.885218)

[7. (Peschl2017Myelin) Patrick Peschl, Monika Bradl, Romana Höftberger, Thomas Berger, and Markus Reindl. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Frontiers in Immunology, May 2017. URL: http://dx.doi.org/10.3389/fimmu.2017.00529, doi:10.3389/fimmu.2017.00529. This article has 180 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2017.00529)

[8. (Marignier2021Myelinoligodendrocyte) Romain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, Anne-Katrin Pröbstel, Orhan Aktas, Harry Alexopoulos, Maria-Pia Amato, Nasrin Asgari, Brenda Banwell, Jeffrey Bennett, Fabienne Brilot, Marco Capobianco, Tanuja Chitnis, Olga Ciccarelli, Kumaran Deiva, Jérôme De Sèze, Kazuo Fujihara, Anu Jacob, Ho Jin Kim, Ingo Kleiter, Hans Lassmann, Maria-Isabel Leite, Christopher Linington, Edgar Meinl, Jacqueline Palace, Friedemann Paul, Axel Petzold, Sean Pittock, Markus Reindl, Douglas Kazutoshi Sato, Krzysztof Selmaj, Aksel Siva, Bruno Stankoff, Mar Tintore, Anthony Traboulsee, Patrick Waters, Emmanuelle Waubant, Brian Weinshenker, Tobias Derfuss, Sandra Vukusic, and Bernhard Hemmer. Myelin-oligodendrocyte glycoprotein antibody-associated disease. The Lancet Neurology, 20(9):762–772, September 2021. URL: http://dx.doi.org/10.1016/S1474-4422(21)00218-0, doi:10.1016/s1474-4422(21)00218-0. This article has 388 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/S1474-4422(21)00218-0)

[9. (BELFIORE2002The) MARCO BELFIORE, LAURA D. MATHIES, PAOLO PUGNALE, GARY MOULDER, ROBERT BARSTEAD, JUDITH KIMBLE, and ALESSANDRO PUOTI. The mep-1 zinc-finger protein acts with mog deah box proteins to control gene expression via the fem-3 3??? untranslated region in caenorhabditis elegans. RNA, 8(6):725–739, June 2002. URL: http://dx.doi.org/10.1017/s1355838202028595, doi:10.1017/s1355838202028595. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1017/s1355838202028595)

[10. (Macrini2021Features) Caterina Macrini, Ramona Gerhards, Stephan Winklmeier, Lena Bergmann, Simone Mader, Melania Spadaro, Atay Vural, Michaela Smolle, Reinhard Hohlfeld, Tania Kümpfel, Stefan F Lichtenthaler, Henri G Franquelim, Dieter Jenne, and Edgar Meinl. Features of mog required for recognition by patients with mog antibody-associated disorders. Brain, 144(8):2375–2389, March 2021. URL: http://dx.doi.org/10.1093/brain/awab105, doi:10.1093/brain/awab105. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awab105)

[11. (Chasapis2022The) Christos T. Chasapis, Konstantinos Kelaidonis, Harry Ridgway, Vasso Apostolopoulos, and John M. Matsoukas. The human myelin proteome and sub-metalloproteome interaction map: relevance to myelin-related neurological diseases. Brain Sciences, 12(4):434, March 2022. URL: http://dx.doi.org/10.3390/brainsci12040434, doi:10.3390/brainsci12040434. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/brainsci12040434)

[12. (Sun2020Myelin) Xiaobo Sun, Wei Qiu, Jingqi Wang, Shisi Wang, Yuge Wang, Xiaonan Zhong, Chunxin Liu, Chunping Cui, Hai Hong, Hui Yang, Xiao-Jing Li, Zhengqi Lu, Xueqiang Hu, Allan G Kermode, and Lisheng Peng. Myelin oligodendrocyte glycoprotein-associated disorders are associated with hla subtypes in a chinese paediatric-onset cohort. Journal of Neurology, Neurosurgery &amp; Psychiatry, 91(7):733–739, May 2020. URL: http://dx.doi.org/10.1136/jnnp-2019-322115, doi:10.1136/jnnp-2019-322115. This article has 19 citations.](https://doi.org/10.1136/jnnp-2019-322115)

[13. (Corbali2023Pathophysiology) Osman Corbali and Tanuja Chitnis. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. Frontiers in Neurology, February 2023. URL: http://dx.doi.org/10.3389/fneur.2023.1137998, doi:10.3389/fneur.2023.1137998. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2023.1137998)